First-In-Human (FIH) Study of W0180 as Single Agent and in Combination With Pembrolizumab in Adults With Locally Advanced or Metastatic Solid Tumors

Inclusion Criteria:

1. Histologically or cytologically confirmed diagnosis of locally advanced or metastatic solid tumors, whose disease has progressed or for whom no further standard therapy is available or appropriate
2. Evidence of measurable disease as determined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (or modified RECIST 1.1 for mesothelioma)
3. Adequate blood counts at baseline
4. Adequate liver function at screening and baseline
5. Sexually active participants must use medically acceptable methods of contraception during the course of this study

Exclusion Criteria:

1. Participants previously treated with an anti-V-domain Ig suppressor of T cell activation (VISTA) (small molecule or antibody) agent
2. Participants with known central nervous system (CNS) metastases and/or carcinomatous meningitis
3. History of severe hypersensitivity reactions to other monoclonal antibodies
4. Positive for hepatitis B virus(HBV), hepatitis C virus (HCV) or HIV infection
5. History of anti-cancer therapies within the last 4 weeks (or <=5 half-lives for targeted agents) prior to initiating study treatment.